Tivic Health Systems Inc. (NASDAQ:TIVC) saw its shares climb 5% after announcing that shareholders had approved key measures critical to the company’s ongoing strategic pivot during its annual meeting held on June 30, 2025.
Among the approved items was the authorization to issue equity for the company’s exclusive global licensing rights to Entolimod and Entolasta—two immunotherapeutic candidates in development for acute radiation syndrome, neutropenia, and other oncology and hematology applications. Shareholders also gave the green light to additional equity issuance connected to previously disclosed financing agreements. Both approvals were necessary to remain compliant with Nasdaq listing requirements.
“We have established a strong foundation for Tivic’s expansion into biopharmaceutical markets — starting with commercialization of Entolimod for two large-market indications,” said Tivic CEO Jennifer Ernst in the press release.
The company also announced changes to its executive team. Lisa Wolf has been officially named Chief Financial Officer after serving in the interim role for the past nine months. Meanwhile, Blake Gurfein, who has held the position of Chief Scientific Officer for eight years, will transition to a consulting role, where he will continue contributing to Tivic’s Vagus Nerve Stimulation program.
Tivic Health, which has described itself as a diversified immunotherapeutics company, initially gained recognition for its FDA-cleared product ClearUP and is now broadening its focus with the addition of these licensed treatments.